Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 7/20 | 0.60 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.59 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.57 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.57 |
| ▸ | NT5E | P21589 | 2/20 | 0.55 |
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.51 |
| ▸ | HINT1 | P49773 | 2/20 | 0.49 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL263726 | 0.87 | IMPDH2 (0.75) | IMPDH2IMPDH1TAS1R3TAS1R1NT5E | |
| SCHEMBL14929355 | 0.85 | IMPDH2 (0.64) | IMPDH2IMPDH1TAS1R3TAS1R1NT5E | |
| SCHEMBL14946391 | 0.85 | IMPDH2 (0.64) | IMPDH2IMPDH1TAS1R3TAS1R1NT5E | |
| SCHEMBL18574075 | 0.85 | IMPDH2 (0.64) | IMPDH2IMPDH1TAS1R3TAS1R1NT5E | |
| SCHEMBL16508951 | 0.84 | IMPDH2 (0.66) | IMPDH2IMPDH1TAS1R3TAS1R1NT5E | |
| SCHEMBL18574074 | 0.84 | P2RX3 (0.65) | IMPDH2IMPDH1TAS1R3TAS1R1NT5E | |
| SCHEMBL14929515 | 0.84 | P2RX3 (0.65) | IMPDH2IMPDH1TAS1R3TAS1R1NT5E | |
| SCHEMBL30363045 | 0.84 | P2RX3 (0.65) | IMPDH2IMPDH1TAS1R3TAS1R1NT5E | |
| SCHEMBL14946399 | 0.84 | P2RX3 (0.65) | IMPDH2IMPDH1TAS1R3TAS1R1NT5E | |
| Benzene SCHEMBL159359 | 0.82 | IMPDH2 (0.54) | IMPDH2IMPDH1TAS1R3TAS1R1NT5E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108533-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-05-03 | — | — | US | claimed |
| EP-2424874-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL ANGENTS | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2012-03-07 | — | — | EP | claimed |
| WO-2010125200-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL ANGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2010-11-04 | — | — | WO | claimed |
| US-20120108533-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2012-05-03 | — | — | US | disclosed |
| EP-2424874-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL ANGENTS | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2012-03-07 | — | — | EP | disclosed |
| WO-2010125200-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL ANGENTS | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2010-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108533-A1 | NOVEL PHOSPHATE MODIFIED NUCLEOSIDES USEFUL AS SUBSTRATES FOR POLYMERASES AND AS ANTIVIRAL AGENTS | PNP, TYMP, MTAP | IMPDH2 121/4885IMPDH1 57/4885TAS1R3 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.